Article: E
2023 Volume 12, Issue 5, Page(s) 402–408
Abstract: Background: No study has compared EUS-guided radiofrequency ablation (EUS-RFA) plus systemic chemotherapy (CMT) with CMT alone for unresectable pancreatic ductal adenocarcinoma.: Methods: This study compared the results of treatment in patients ... ...
Abstract | Background: No study has compared EUS-guided radiofrequency ablation (EUS-RFA) plus systemic chemotherapy (CMT) with CMT alone for unresectable pancreatic ductal adenocarcinoma. Methods: This study compared the results of treatment in patients receiving EUS-RFA plus concomitant CMT (group A; Results: From July 2017 to August 2018, 4 and 2 patients from groups A and B, respectively, withdrew from the study because of progression of the disease. In total, 10 and 12 patients from groups A and B, respectively, completed the study. All 30 EUS-RFA procedures were successful. Mean maximal tumor diameter before treatment of group A ( Conclusions: In this study, the mean tumor diameter of group B was significantly increased after the treatment. Group A had a significantly higher rate of necrosis of tumor and required less narcotic. |
---|---|
Language | English |
Publishing date | 2023-10-23 |
Publishing country | China |
Document type | Journal Article |
ZDB-ID | 2998317-4 |
ISSN | 2226-7190 ; 2303-9027 |
ISSN (online) | 2226-7190 |
ISSN | 2303-9027 |
DOI | 10.1097/eus.0000000000000003 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.